Predicting changes in hypertension control using electronic health records from a chronic disease management program

OBJECTIVE Common chronic diseases such as hypertension are costly and difficult to manage. Our ultimate goal is to use data from electronic health records to predict the risk and timing of deterioration in hypertension control. Towards this goal, this work predicts the transition points at which hypertension is brought into, as well as pushed out of, control. METHOD In a cohort of 1294 patients with hypertension enrolled in a chronic disease management program at the Vanderbilt University Medical Center, patients are modeled as an array of features derived from the clinical domain over time, which are distilled into a core set using an information gain criteria regarding their predictive performance. A model for transition point prediction was then computed using a random forest classifier. RESULTS The most predictive features for transitions in hypertension control status included hypertension assessment patterns, comorbid diagnoses, procedures and medication history. The final random forest model achieved a c-statistic of 0.836 (95% CI 0.830 to 0.842) and an accuracy of 0.773 (95% CI 0.766 to 0.780). CONCLUSIONS This study achieved accurate prediction of transition points of hypertension control status, an important first step in the long-term goal of developing personalized hypertension management plans.

[1]  A. Huebschmann,et al.  Reducing Clinical Inertia in Hypertension Treatment: A Pragmatic Randomized Controlled Trial , 2012, Journal of clinical hypertension.

[2]  A. Dominiczak,et al.  2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) , 2007, European heart journal.

[3]  A. Dominiczak,et al.  2007 ESH‐ESC Guidelines for the management of arterial hypertension , 2007 .

[4]  Leo Breiman,et al.  Random Forests , 2001, Machine Learning.

[5]  Daniel W. Jones,et al.  Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. , 2003, Hypertension.

[6]  A. Zanchetti,et al.  Cohort profile: The Gubbio Population Study. , 2014, International journal of epidemiology.

[7]  D. Lackland,et al.  Hypertension risk prediction: an important but complicated assessment. , 2010, Hypertension.

[8]  Farzad Hadaegh,et al.  A point-score system superior to blood pressure measures alone for predicting incident hypertension: Tehran Lipid and Glucose Study , 2011, Journal of hypertension.

[9]  Suzette J. Bielinski,et al.  Use of diverse electronic medical record systems to identify genetic risk for type 2 diabetes within a genome-wide association study , 2012, J. Am. Medical Informatics Assoc..

[10]  Michael Böhm,et al.  2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). , 2007, Journal of hypertension.

[11]  Abel N. Kho,et al.  A Highly Specific Algorithm for Identifying Asthma Cases and Controls for Genome-Wide Association Studies , 2009, AMIA.

[12]  Geoffrey A Head,et al.  Definition of ambulatory blood pressure targets for diagnosis and treatment of hypertension in relation to clinic blood pressure: prospective cohort study , 2010, BMJ : British Medical Journal.

[13]  Fei Wang,et al.  ICDA: A Platform for Intelligent Care Delivery Analytics , 2012, AMIA.

[14]  Morris J. Brown,et al.  Double-blind, placebo-controlled crossover comparison of five classes of antihypertensive drugs , 2002, Journal of hypertension.

[15]  Brian W. Ward,et al.  Prevalence of Multiple Chronic Conditions Among US Adults: Estimates From the National Health Interview Survey, 2010 , 2013, Preventing chronic disease.

[16]  Eric Boerwinkle,et al.  Demographic, environmental, and genetic predictors of metabolic side effects of hydrochlorothiazide treatment in hypertensive subjects. , 2005, American journal of hypertension.

[17]  W. Kannel,et al.  Some lessons in cardiovascular epidemiology from Framingham. , 1976, The American journal of cardiology.

[18]  Ulrich Tholl,et al.  Measuring blood pressure: pitfalls and recommendations. , 2004, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[19]  Christopher G. Chute,et al.  A Genome-Wide Association Study of Red Blood Cell Traits Using the Electronic Medical Record , 2010, PloS one.

[20]  Barry R. Davis,et al.  Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group. , 2000, JAMA.

[21]  Michael Böhm,et al.  Antihypertensive drug therapy and blood pressure control in men and women: an international perspective , 2010, Journal of Human Hypertension.

[22]  Carl J Pepine,et al.  A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. , 2003, JAMA.

[23]  Bernard J. Gersh,et al.  Treatment of Hypertension in the Prevention and Management of Ischemic Heart Disease: A Scientific Statement From the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention , 2007, Circulation.

[24]  D. Levy,et al.  A Risk Score for Predicting Near-Term Incidence of Hypertension: The Framingham Heart Study , 2008, Annals of Internal Medicine.

[25]  Barry R Davis,et al.  Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril. , 2005, JAMA.

[26]  Arno Lukas,et al.  Body mass index is the main risk factor for arterial hypertension in young subjects without major comorbidity , 2003, European journal of clinical investigation.

[27]  H. Perry,et al.  Antihypertensive efficacy of treatment regimens used in Veterans Administration hypertension clinics. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. , 1998, Hypertension.

[28]  W. Cushman,et al.  Home and clinic blood pressure responses in elderly individuals with systolic hypertension. , 2012, Journal of the American Society of Hypertension : JASH.

[29]  A. Dominiczak,et al.  2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. , 2007, Journal of hypertension.

[30]  Lin Chen,et al.  Importance of multi-modal approaches to effectively identify cataract cases from electronic health records , 2012, J. Am. Medical Informatics Assoc..

[31]  Fei Wang,et al.  Combining Knowledge and Data Driven Insights for Identifying Risk Factors using Electronic Health Records , 2012, AMIA.

[32]  Barry R. Davis,et al.  Outcomes in Hypertensive Black and Nonblack Patients Treated With Chlorthalidone, Amlodipine, and Lisinopril , 2005 .

[33]  Devin M Mann,et al.  Comparison of the Framingham Heart Study Hypertension Model With Blood Pressure Alone in the Prediction of Risk of Hypertension: The Multi-Ethnic Study of Atherosclerosis , 2010, Hypertension.

[34]  Melissa A. Basford,et al.  Validation of electronic medical record-based phenotyping algorithms: results and lessons learned from the eMERGE network. , 2013, Journal of the American Medical Informatics Association : JAMIA.

[35]  Morris J. Brown,et al.  Personalised medicine for hypertension , 2011, BMJ : British Medical Journal.

[36]  J. Cutler,et al.  Treatment of Mild Hypertension Study. Final results. Treatment of Mild Hypertension Study Research Group. , 1993, JAMA.

[37]  Y. Kawano,et al.  Comparison of first-line antihypertensive drugs by a randomized cross-over method--a preliminary report. , 1995, Hypertension research : official journal of the Japanese Society of Hypertension.

[38]  V. Durkalski,et al.  Therapeutic Inertia Is an Impediment to Achieving the Healthy People 2010 Blood Pressure Control Goals , 2006, Hypertension.

[39]  C. Lewis,et al.  Treatment of Mild Hypertension Study: Final Results , 1993 .

[40]  D. Roden,et al.  Development of a Large‐Scale De‐Identified DNA Biobank to Enable Personalized Medicine , 2008, Clinical pharmacology and therapeutics.

[41]  Roland E Schmieder,et al.  Clinical situations associated with difficult-to-control hypertension , 2013, Journal of hypertension.

[42]  Vital signs: awareness and treatment of uncontrolled hypertension among adults--United States, 2003-2010. , 2012, MMWR. Morbidity and mortality weekly report.

[43]  Jiang He,et al.  Primary prevention of hypertension: clinical and public health advisory from The National High Blood Pressure Education Program. , 2002, JAMA.

[44]  Hua Xu,et al.  Portability of an algorithm to identify rheumatoid arthritis in electronic health records , 2012, J. Am. Medical Informatics Assoc..

[45]  David A Calhoun,et al.  Pathogenesis of Hypertension , 2003, Annals of Internal Medicine.

[46]  Domingo Orozco-Beltrán,et al.  Clinical Inertia in Poorly Controlled Elderly Hypertensive Patients: A Cross-Sectional Study in Spanish Physicians to Ascertain Reasons for Not Intensifying Treatment , 2013, American Journal of Cardiovascular Drugs.

[47]  Edward B. Nelson,et al.  The treatment of mild hypertension study. , 1993 .

[48]  I. Kohane,et al.  Electronic medical records for discovery research in rheumatoid arthritis , 2010, Arthritis care & research.

[49]  Thomas Hedner,et al.  Randomised trial of effects of calcium antagonists compared with diuretics and β-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study , 2000, The Lancet.

[50]  A. Scuteri,et al.  Do hypertensive individuals have enlarged aortic root diameters? Insights from studying the various subtypes of hypertension. , 2008, American journal of hypertension.

[51]  Wenyaw Chan,et al.  Effect of a Physician Uncertainty Reduction Intervention on Blood Pressure in Uncontrolled Hypertensives—A Cluster Randomized Trial , 2012, Journal of General Internal Medicine.

[52]  B Waeber,et al.  Individual responses to converting enzyme inhibitors and calcium antagonists. , 1988, Hypertension.

[53]  Tara Gomes,et al.  Chlorthalidone Versus Hydrochlorothiazide for the Treatment of Hypertension in Older Adults , 2013, Annals of Internal Medicine.

[54]  Peggy L Peissig,et al.  Cataract research using electronic health records , 2011, BMC ophthalmology.

[55]  M. J. Ashby,et al.  Optimisation of antihypertensive treatment by crossover rotation of four major classes , 1999, The Lancet.

[56]  Daniel W. Jones,et al.  The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. , 2003, JAMA.

[57]  B. Waeber,et al.  Therapeutic strategies to improve control of hypertension , 2013, Journal of hypertension.

[58]  B. Davis,et al.  Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). , 2002, JAMA.

[59]  J. Izzo,et al.  Mechanisms and management of hypertensive heart disease: from left ventricular hypertrophy to heart failure. , 2004, The Medical clinics of North America.

[60]  Jun Ma,et al.  Screening, Treatment, and Control of Hypertension in US Private Physician Offices, 2003–2004 , 2008, Hypertension.